Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy


Brachat A. H. , Grom A. A. , Wulffraat N., Brunner H. I. , Quartier P., Brik R., ...Daha Fazla

ARTHRITIS RESEARCH & THERAPY, cilt.19, 2017 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 19
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1186/s13075-016-1212-x
  • Dergi Adı: ARTHRITIS RESEARCH & THERAPY

Özet

Background: Canakinumab is a human anti-interleukin-1 beta (IL-1 beta) monoclonal antibody neutralizing IL-1 beta-mediated pathways. We sought to characterize the molecular response to canakinumab and evaluate potential markers of response using samples from two pivotal trials in systemic juvenile idiopathic arthritis (SJIA).